Innovent Rises 3% as Eli Lilly Pact Finalizes

Edgen Stock·Mar 25 2026, 01:51

Share to

Share to

Copy link

Key Takeaways

A strategic collaboration between Innovent Bio and pharmaceutical giant Eli Lilly became official on March 24, targeting new medicines in oncology and immunology. The news, coupled with a major clinical trial success for Innovent's eye drug a day prior, highlights the company's robust R&D capabilities and reinforces its position as a key strategic partner, not an acquisition target.

Partnership Solidified: The strategic collaboration with Eli Lilly received early clearance from the U.S. Federal Trade Commission, making the agreement effective on March 24.
Market Reacts Positively: Innovent's Hong Kong-listed shares (01801.HK) rose 3.004% on the news, as the company explicitly clarified the deal is a partnership, not an acquisition.
Pipeline Strength Validated: A day earlier, Innovent announced its self-developed eye drug, IBI302, met its primary endpoint in a Phase 3 trial, with 72.8% of patients achieving a 16-week dosing interval.

Innovent Shares Gain 3% as Eli Lilly Pact Finalizes

Innovent Bio's (01801.HK) strategic partnership with Eli Lilly (LLY.US) became effective on March 24, propelling the company's stock up 3.004%. The deal, which focuses on developing new oncology and immunology drugs, received early clearance from the U.S. Federal Trade Commission, satisfying all conditions for activation. In response to market speculation, Innovent issued a firm clarification that the agreement is a collaboration and that the company is not engaged in any acquisition talks. The stock's positive movement occurred despite significant short interest, with short selling volume reported at $155.34 million, representing an 18.956% ratio as of the market close on March 24.

New Eye Drug Succeeds in Phase 3, Validating R&D Pipeline

Just a day before the partnership news, on March 23, Innovent announced its proprietary eye disease treatment, efdamrofusp alfa (IBI302), met its primary endpoint in a Phase 3 study for neovascular age-related macular degeneration (nAMD). The trial demonstrated that the drug's improvement in vision was non-inferior to aflibercept, a market-leading treatment. Critically, the study showed a significant competitive advantage in dosing frequency, with 72.8% of patients achieving a 16-week interval between treatments. The results, from a study of 600 participants, also suggested IBI302 has the potential to reduce the risk of macular atrophy, with an incidence rate of 1.5% compared to 2.9% in the aflibercept group. This clinical success underscores Innovent's internal R&D strength, positioning it as a valuable innovator in the biopharmaceutical sector.

We will actively prepare to submit a New Drug Application (NDA), striving to provide a more convenient, patient-friendly, and highly efficacious treatment option for nAMD patients as early as possible.

— Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent.